Advanced Research in Heme Oxygenase
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".
Deadline for manuscript submissions: 31 July 2024 | Viewed by 249
Special Issue Editors
Interests: heme oxygenase; bilirubin; oxidative stress; nuclear receptors; fatty liver; glucocorticoid receptor; PPARs
Special Issues, Collections and Topics in MDPI journals
Interests: obesity; diabetes; hypertension; cardiovascular disease; heme oxygenase; bilirubin; biliverdin reductase; antioxidants
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Heme oxygenase (Hmox) has been studied for many decades and is known to be the enzyme responsible for the breakdown of heme, which occurs in all cells in the body. It generates carbon monoxide (CO), biliverdin, which is reduced by biliverdin reductase to bilirubin, and free iron. Heme oxygenase and its related enzymes and metabolites play an important role in several physiological and pathological processes, including cancer, diabetes, heart and kidney disease, hypertension, inflammation, obesity, and neurological diseases. This Special Issue solicits exciting new advances in heme oxygenase biology, its related enzymes for synthesis or catabolism, and its metabolites. The latest in preclinical and clinical trials and timely reviews highlighting the importance of heme oxygenase and its related metabolites will be incorporated into the Special Issue. The goal is to expand upon what has been known about Hmox and extend this into new advancements, whether that might be detection instruments, new ligand agonists or antagonists, and possible new discoveries not yet known.
Dr. Terry D Hinds, Jr.
Dr. David E. Stec
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- heme oxygenase
- bilirubin
- iron
- biliverdin reductase
- ferritin
- feroapoptosis
- carbon monoxide
